Summary of Tempus AI FY Conference Call (September 08, 2025) Company Overview - **Company**: Tempus AI (NasdaqGS:TEM) - **Industry**: Genomics and Data Analytics in Healthcare Key Points Financial Performance - **Q2 Growth**: - Genomics business experienced a growth acceleration from 20% year-over-year in Q1 to 26% in Q2 [2] - Genomics revenue exceeded 30% growth due to reimbursement tailwinds [2] - Adjusted EBITDA improved by approximately $10 million quarter-over-quarter, with expectations to achieve positive adjusted EBITDA in 2025 [2] Business Expansion and Strategy - **Revenue Milestone**: Company is approaching $1.3 billion in revenue, with both main business segments growing at around 30% [3] - **Acquisition of Amri**: - Expected to enhance growth rates, particularly in rare diseases and pediatrics [5] - Q2 growth for Amri was over 30%, with half attributed to market share gains [14] - **Portfolio Expansion**: Focus on expanding beyond oncology into areas like rare diseases, with expectations of positive reimbursement trends [5] Market Dynamics - **Oncology Landscape**: - There are nearly 15,000 oncologists in the U.S., indicating a significant market for holistic solutions [4] - The company believes that the largest players in minimal residual disease (MRD) will also dominate treatment selection [4] - **Reimbursement Trends**: - Positive trends in securing commercial payer reimbursement, although the landscape remains fragmented [9] - MRD tests currently lack reimbursement, with expectations for improvement by the end of the year [10] Data Infrastructure and Technology - **Data Investments**: - Tempus has invested heavily in building a robust technology stack, employing around 700 software engineers [18] - The company has developed proprietary tools to make healthcare data actionable for clients [19] - **Foundation Model**: - A significant project involving over 350 petabytes of data and 1,800 GPUs aimed at generating insights for oncology [28] - The model is expected to enhance the personalization and contextualization of tests, improving clinical decision-making [29] AI and Healthcare - **AI Integration**: - The company is a leader in applying AI to diagnostics, with several FDA-approved algorithms [37] - There is a recognized need for reimbursement mechanisms for AI-driven solutions in healthcare [36] - **Future Outlook**: - AI is anticipated to have a transformative impact on healthcare, with significant potential for cost savings and improved outcomes [61] Challenges and Considerations - **Market Competition**: - The company faces competition in securing reimbursement and market share, particularly in the MRD space [10] - **Long-term Growth**: - While current growth rates are strong, the sustainability of share gains from competitors is uncertain [14] Additional Insights - **Client Engagement**: - The company has established long-term contracts with major pharmaceutical clients, indicating strong demand for its data services [33] - **Product Differentiation**: - Tempus aims to differentiate its genomic tests through integrated data insights, enhancing the value proposition for physicians [27] This summary encapsulates the key insights and developments discussed during the Tempus AI FY Conference Call, highlighting the company's growth trajectory, strategic initiatives, and the evolving landscape of genomics and data analytics in healthcare.

Core Insights - SOPHiA GENETICS has announced a collaboration with Jessa Ziekenhuis to enhance genomic testing and oncology research for cancer patients in Belgium [1][8] - The partnership aims to unify next-generation sequencing (NGS) workflows under a single platform, improving efficiency and compliance with national guidelines [2][5] Group 1: Collaboration Details - Jessa Ziekenhuis processes over 3,000 oncology DNA and RNA samples annually and will implement SOPHiA DDM™ across its pathology operations [2] - The collaboration will involve six SOPHiA GENETICS applications tailored for solid tumors, hematologic malignancies, and liquid biopsy analysis [3] - The integration of SOPHiA GENETICS' cloud-based platform with Jessa Ziekenhuis's Laboratory Information Management System (LIMS) will streamline operations [4] Group 2: Expected Benefits - Jessa Ziekenhuis anticipates a reduction in hands-on time by 30-50% and overall costs by up to 25% through the unified NGS operation [5] - The collaboration will enhance testing turnaround times and improve the scalability of sequencing services [5][6] - The SOPHiA DDM™ Dispatch feature will allow Jessa Ziekenhuis to share a NovaSeq sequencer with AZ Delta, optimizing sequencing capacity and knowledge sharing [6] Group 3: Strategic Importance - The partnership exemplifies SOPHiA GENETICS' commitment to supporting healthcare institutions in scaling genomics capabilities while ensuring quality and efficiency [8] - This collaboration strengthens SOPHiA GENETICS' presence in European hospital networks, promoting data-driven precision medicine [8][9]

Core Points - ProPhase Labs Inc. will participate in a live Virtual Non-Deal Roadshow on September 4, 2025, to discuss its latest investor presentation [2][3] - The presentation will cover a general overview of the company, its crypto treasury strategy, significant liquidity events, and the cancellation of the Equity Line of Credit (ELOC) [3] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on healthcare innovation [5] - The company aims to revolutionize healthcare through Whole Genome Sequencing solutions and diagnostic developments, including a test for early detection of esophageal cancer [5] - ProPhase Labs is committed to executional excellence, smart diversification, and a synergistic omni-channel approach to health and wellness solutions [5]

Core Viewpoint - ProPhase Labs, Inc. is positioning itself for innovative growth through a series of proposals aimed at enhancing its financial flexibility and strategic resources, particularly in the biotech, genomics, and digital asset sectors [3][4][9] Group 1: Proxy Statement and Shareholder Meeting - ProPhase filed a definitive proxy statement with the SEC on August 15, 2025, and received a "no further comments" letter from the SEC on August 18, 2025, indicating the completion of the review process [1] - The Special Meeting of Shareholders has been rescheduled from August 29, 2025, to September 9, 2025, to ensure proper dissemination of definitive proxy materials [2] Group 2: Proposals and Strategic Initiatives - The Board of Directors recommends shareholders vote 'FOR' all proposals, which include advancing a crypto treasury strategy and supporting the commercialization of the BE-Smart™ Esophageal Cancer test [3][4] - Key proposals include increasing authorized shares from 50 million to 1 billion and authorizing a $15 million share repurchase program, aimed at providing flexibility for the crypto treasury strategy [4][5] - The increase in authorized shares is intended to attract major players in the crypto industry and facilitate the establishment of new crypto-related verticals [5] Group 3: Financial Strategy and Future Outlook - The management is exploring a crypto treasury strategy that could leverage potential liquidity events, including a projected $50 million from the Crown Medical Collections initiative and a possible sale of Nebula Genomics [6] - CEO Ted Karkus highlighted the company's previous success in raising capital without diluting shareholder value and emphasized the commitment to building shareholder value through strategic financing [7] - The company aims to utilize potential liquidity events to invest in a crypto treasury strategy that could generate yield and earnings for shareholders [6][7] Group 4: Shareholder Engagement - ProPhase emphasizes the importance of proactive shareholder engagement and encourages shareholders to review the definitive proxy statement for detailed information on the proposals [9][10]

Investor FORWARD LOOKING STATEMENTS Except for the historical information contained herein, this document contains forward tooking statements within the meaning of the Privates Securities Litigation Reform A stakements regarding our stralegy, plans, objectives and intitatives, including our expectations regarding the tubue revenue growth potential of each of our substitiance, for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our effor ...

Core Insights - ProPhase Labs has reported significant operational and financial improvements, including a strengthened equity position and a focus on transformational growth catalysts [1][7][11] - The company has been granted a key U.S. patent for its BE-Smart Esophageal Adenocarcinoma Risk Assessment test, which is expected to accelerate its commercialization pathway [4][12] - ProPhase is actively pursuing non-dilutive funding strategies, including a $50 million opportunity with Crown Medical Collections, which could provide significant cash flow in the second half of 2025 [6][10] Financial Performance - For the three months ended June 30, 2025, net revenue was $1.2 million, a decrease from $1.5 million in the same period in 2024 [15] - The cost of revenues for the same period was $0.5 million, down from $1.7 million in Q2 2024, resulting in a gross margin profit of $0.7 million compared to a loss of $0.2 million in the prior year [16][17] - General and administrative expenses decreased to $4.6 million from $6.9 million year-over-year, primarily due to reduced personnel expenses and overhead costs [18] Operational Improvements - The company has streamlined operations, reducing operating expenses by over 35% year-to-date through disciplined portfolio optimization and cost controls [7][11] - ProPhase eliminated high-cost debt, repaying the majority of its merchant cash advance debt, which has increased financial flexibility [7] - The strategic portfolio realignment, including the sale of PMI and Pharmaloz Real Estate, generated an $8.7 million gain and eliminated over $20 million in debt/liabilities [7] Future Strategies - ProPhase is exploring a new Crypto Treasury Strategy to capture upside without sacrificing shareholder value, involving the acquisition and long-term holding of select digital assets [8][9] - The Board is evaluating guardrails for share issuance to protect shareholder interests while allowing flexibility for potential capital raises [9][10] - The company aims to leverage liquidity events, including the Crown Medical Collections initiative and a possible sale of Nebula Genomics, to fund its crypto treasury strategy without issuing new shares [10]

Core Viewpoint - ProPhase Labs Inc. will present its second quarter 2025 financial results on August 13, 2025, at 2:00 pm EDT through a virtual conference call [1][2]. Group 1: Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on building a healthier world through innovation and actionable insights [4]. - The company is known for its Whole Genome Sequencing solutions and diagnostic developments, including a test for early detection of esophageal cancer [4]. - ProPhase Labs aims to develop, manufacture, and commercialize health and wellness solutions, emphasizing executional excellence and smart diversification [4]. Group 2: Event Details - A press release detailing the financial results will be issued prior to the virtual conference call [2]. - Stakeholders, investors, and individual followers are invited to register for the live event, with a replay available on the company's investor website afterward [2][3].

Financial Data and Key Metrics Changes - Revenue increased by 89.6% to $314.6 million, with Genomics revenue rising 115% to $241.8 million driven by volume growth in oncology [4][5] - Quarterly gross profit reached $195 million, reflecting a 160% increase, while adjusted EBITDA improved from negative $16 million to negative $5.6 million [5][6] - Full year 2025 revenue guidance was raised to $1.26 billion, with an adjusted EBITDA forecast of approximately $5 million, indicating a $110 million improvement over the previous year [6] Business Line Data and Key Metrics Changes - Genomics revenue growth was primarily attributed to oncology volume growth, which increased from 20% to 26% [4] - Data and Services revenue grew by 35.7% to approximately $73 million, led by a 41% increase in data licensing from Incyte [5] Market Data and Key Metrics Changes - Significant sequential volume growth was observed across the entire oncology testing compendium, with hereditary volumes also exceeding expectations [12][14] - The company is capturing market share from historical players who have reduced their presence in the market, indicating strong tailwinds in the overall space [15] Company Strategy and Development Direction - The company is focused on maintaining growth while approaching adjusted EBITDA breakeven, with plans to continue investing in growth opportunities [6][43] - There is a strong emphasis on AI and data integration into diagnostics, with expectations that this will transform R&D portfolios and patient care [49][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, highlighting the importance of long-term strategies over short-term gains [97] - The company anticipates that reimbursement for MRD (Minimal Residual Disease) testing will occur in 2026, which is expected to significantly boost volumes [58][90] Other Important Information - The company issued $750 million of 0.75% convertible notes to reduce interest expenses and improve cash flow [6] - The data business is expected to grow at around 30% for the year, with Q4 typically being the largest revenue quarter [62] Q&A Session Summary Question: Can you elaborate on the strong core genomic volumes in the quarter? - Management noted significant sequential volume growth across oncology testing, driven by sales force efficiencies and technology improvements [12][13] Question: How should we think about the cadence of ASP as you migrate volumes to CDx? - ASPs are expected to see incremental gains as the company approaches its target of migrating 40% of XT volume to CDx by year-end [22] Question: Can you discuss bookings trends for Insights and Trials? - Bookings were strong due to the AstraZeneca Pathos deal, with total contract value up materially [30] Question: What is the pipeline for future partnerships with pharma? - The pipeline remains robust, with no significant pressure from competitors, and the company expects to close large deals in the future [39] Question: How do you balance investments among various parts of the business? - The company aims to maintain discipline in investments while focusing on long-term growth and adjusted EBITDA positivity [43][86] Question: What are the expectations for the back half of the year in the data business? - The data business is expected to grow slightly above 30% for the year, with Q4 anticipated to be the largest revenue quarter [62] Question: How is the liquid biopsy business performing? - The liquid biopsy franchise is growing faster than the market, with a competitive product set [68][70] Question: What is the company's appetite for acquisitions or partnerships? - The company remains opportunistic but disciplined in pursuing acquisitions that align with its strategic goals [78][80] Question: How significant will MRD be in the oncology volumes? - MRD is expected to become a larger part of the business once reimbursement is secured, which will drive unit growth [90][94]

Core Viewpoint - Bionano Genomics, Inc. will host a conference call and live webcast on August 14, 2025, to report its financial results for the second quarter of 2025 and discuss recent corporate developments [1]. Group 1: Conference Call & Webcast Details - The conference call is scheduled for Thursday, August 14, 2025, at 4:30 p.m. Eastern Time [2]. - Participants can register for the call and access a live webcast through the company's investor relations page [2]. - A replay of the conference call and webcast will be available on Bionano's investor relations website for at least 30 days [2]. Group 2: Company Contacts - Erik Holmlin is the CEO of Bionano Genomics, and can be contacted at +1 (858) 888-7610 or via email at eholmlin@bionano.com [3]. - Investor relations are managed by Kelly Gura from Gilmartin Group, who can be reached at +1 (212) 229-6163 or IR@bionano.com [3].

Industry Overview - Genomics is a rapidly evolving field that studies the complete set of genes and their interactions, attracting significant attention from pharmaceutical and biotech companies [1][2] - The genomics market is projected to reach $157.47 billion by 2033, while the global synthetic biology market was valued at $16.22 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [6] Technological Advancements - Breakthroughs in genetic sequencing have drastically reduced the cost, accuracy, and time required to map an individual's genome, leading to innovative applications in healthcare and diagnostics [4] - Genome editing technologies, particularly CRISPR/Cas9, are being developed to treat diseases caused by genetic variants, with companies like CRISPR Therapeutics AG and Beam Therapeutics at the forefront [5] Key Companies - Illumina is a major player in the genomics sector, providing sequencing and array-based solutions for genetic analysis [4] - Intellia Therapeutics focuses on CRISPR-based therapies, with lead candidates targeting ATTR amyloidosis and HAE, and is collaborating with Regeneron for its investigational therapy [8][9][10] - Editas Medicine is developing treatments using its proprietary genome editing platform, with successful preclinical proof of concept for editing hematopoietic stem cells and liver cells [12][13] - Prime Medicine is advancing programs for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file for investigational new drugs in 2026 [14][15][16]